Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v6-FR Version v2-FR
Language French French
Date Updated 2018-06-04 2018-06-04
Drug Identification Number 02458071 02458071
Brand name VYVANSE VYVANSE
Common or Proper name Lisdexamfetamine Dimesylate capsules Lisdexamfetamine Dimesylate capsules
Company Name TAKEDA CANADA INC TAKEDA CANADA INC
Ingredients LISDEXAMFETAMINE DIMESYLATE LISDEXAMFETAMINE DIMESYLATE
Strength(s) 70MG 70MG
Dosage form(s) CAPSULE CAPSULE
Route of administration ORAL ORAL
Packaging size 100's 100's
ATC code N06BA N06BA
ATC description PSYCHOSTIMULANTS AND NOOTROPICS PSYCHOSTIMULANTS AND NOOTROPICS
Reason for shortage Demand increase for the drug. Demand increase for the drug.
Anticipated start date 2018-06-06 2018-06-06
Actual start date
Estimated end date 2018-06-13 2018-06-13
Actual end date
Shortage status Anticipated shortage Anticipated shortage
Tier 3 Status No No
Company comments Shire do not anticipate shortage at the pharmacist level.
Health Canada comments